Expected 10-year treatment cost of XXXX detected within and outside a public screening program in Norway.

@entity1 @entity0 @entity5 @entity513 @entity7634
BACKGROUND: The shift towards earlier stages of disease advancement at diagnosis when introducing mammography screening is expected to affect the treatment costs of @entity0 . MATERIALS AND METHODS: We collected data on hospital resource use in Norway following a @entity0 diagnosis for the period 1 January, 2008 through 31 December, 2009 for @entity1 aged 50-69  years, diagnosed with @entity0 during the period 1 January, 1999 through 31 December, 2009. We estimated treatment costs using a function that included the probability of being at risk for receiving treatment, estimated by means of the Cox proportional hazard model. RESULTS: In total, 16,045 @entity1 were included for the analyses among which 10.5  % died during the study period. The mean 10-year per- @entity1 treatment cost was < @entity7634 >31,940 (95  % CI < @entity7634 >31,030-32,880), and lower for @entity5 detected within the public screening program (< @entity7634 >30,730) than for those detected elsewhere (< @entity7634 >36,230). For @entity513 in situ (DCIS) and @entity5 in stages I thru IV, treatment costs were < @entity7634 >15,740, < @entity7634 >23,570, < @entity7634 >46,550, < @entity7634 >55,230 and < @entity7634 >60,430, respectively. @entity5 occurring within the screening program were generally more resource demanding than both @entity5 detected at screening or elsewhere. CONCLUSIONS: Ten-year treatment costs increased by increasing stage at diagnosis. @entity1 whose @entity5 was detected within the public screening program had lower treatment costs than those detected elsewhere. @entity5 had higher costs than others.
